Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LV232 in Major Depressive Disorder
NCT06828887Phase 2Recruiting
- Sponsor
- Vigonvita Life Sciences
- Start
- Apr 2025
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of LV232 in major depressive disorder (MDD) (4 arms), sponsored by Vigonvita Life Sciences. Primary endpoint: Montgomery-Asberg Depression Rating Scale at 8 weeks. Started Apr 2025; status: recruiting.
02
Drugs
LV232
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06828887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06828887.